-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>/* Style Definitions */ span.
Based on its fully human antibody RenMice platform with completely independent intellectual property rights, Biositu is developing and implementing a large-scale antibody development plan based on in vivo efficacy, the "QianmuwanantiTM " plan, which is developed for 1000+ potential drug targets antibody
At present, there are more than 100 products under development, covering innovative drugs, biological drugs, sustained and controlled release preparations, characteristic generic drugs,
We hope that through this cooperation, Bio-Situ's large-scale new drug R&D platform and Nanjing Chia Tai Tianqing in process development and In terms of industrialization, we will achieve strong alliances, rapidly promote the entry of new drugs into the clinic, and provide effective and safe innovative antibody drugs to protect people's health
”
Biositu is an international biopharmaceutical company with innovative technology-driven research and development of new drugs, and is committed to becoming the birthplace of new drugs in the world
.
Based on its fully human antibody RenMice platform with completely independent intellectual property rights, Biositu is developing and implementing a large-scale antibody development plan based on in vivo efficacy, the "QianmuwanantiTM " plan, which is developed for 1000+ potential drug targets antibody
Nanjing Chia Tai Tianqing is a three-in-one pharmaceutical company with "drug research and development, production and sales".
The company adheres to the research and development concept of "driving innovation with imitation and driving the future with innovation", relying on R&D investment several times the industry average and hundreds of employees.
An expert-level R&D team, and its core products are among the first batch of generic drugs that have passed the consistency evaluation in the country
.
At present, there are more than 100 products under development, covering innovative drugs, biological drugs, sustained and controlled release preparations, characteristic generic drugs,
Adhering to the principle of complementary advantages and win-win cooperation, the two parties will combine Biositu based on the self-developed fully human antibody RenMab platform with independent intellectual property rights and the unique full-chain new drug research and development system, and Nanjing Chia Tai Tianqing's leading domestic research and development, The three platforms of preparations and raw materials are integrated to jointly develop fully human antibody drugs against the targets jointly selected by both parties, taking advantage of the large-scale fully human antibody discovery and screening advantages of Biocytos and Nanjing Chia Tai Tianqing's mature clinical development and strong production.
Together, we can rapidly advance the research and development of drugs for selected targets, with a view to the early launch of drugs and the benefit of patients around the world
.
Xu Dan, Dean of Nanjing Chia Tai Tianqing Research Institute, said: "The Bio-Oceitu RenMab platform can rapidly generate fully human antibodies with high affinity, specificity and diversity.
Quantitative screening and evidence-based in vivo efficacy screening have obtained a large number of candidate antibody molecules with good efficacy and safety
.
We hope that through this cooperation, Bio-Situ's large-scale new drug R&D platform and Nanjing Chia Tai Tianqing in process development and In terms of industrialization, we will achieve strong alliances, rapidly promote the entry of new drugs into the clinic, and provide effective and safe innovative antibody drugs to protect people's health
Dr.
Shen Yuelei, founder, chairman and CEO of Biositu, said: "Nanjing Chia Tai Tianqing has strong scientific research strength and strong industrialization capabilities, and the products under development include innovative drugs, biological drugs, sustained and controlled release preparations, and specialty generic drugs, etc.
It is
believed that based on the respective platform advantages of both parties, we can jointly develop new, efficient, safe antibody drugs with independent intellectual property rights, accelerate the research and development and industrialization of new drugs, meet the unmet clinical needs, and benefit the majority of patients
.
”
